Extended interval dosing of natalizumab in multiple sclerosis
…, S Qureshi, D Okuda, J Kalina, Z Rimler… - Journal of Neurology …, 2016 - jnnp.bmj.com
Background Natalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an
effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal …
effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal …
Retinal optical coherence tomography in neuromyelitis optica
…, U Tanriverdi, A Jacob, S Huda, Z Rimler… - Neurology …, 2021 - AAN Enterprises
Background and Objectives To determine optic nerve and retinal damage in aquaporin-4
antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorders (NMOSD) in a …
antibody (AQP4-IgG)-seropositive neuromyelitis optica spectrum disorders (NMOSD) in a …
Mortality in neuromyelitis optica is strongly associated with African ancestry
MA Mealy, RA Kessler, Z Rimler, A Reid… - Neurology …, 2018 - AAN Enterprises
Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune disease of the
optic nerve, spinal cord, and, less frequently, brain. 1 Severity and degree of recovery from …
optic nerve, spinal cord, and, less frequently, brain. 1 Severity and degree of recovery from …
Longitudinal retinal changes in MOGAD
…, M Pisa, M Radaelli, Z Rimler… - Annals of …, 2022 - Wiley Online Library
Objective Patients with myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐
associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro …
associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro …
Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic …
…, R Curtin, J Pei, K Perdomo, Z Rimler… - Annals of …, 2022 - Wiley Online Library
Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
…, A Patel, V Saha, C Sammarco, Z Rimler… - Multiple Sclerosis and …, 2022 - Elsevier
Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
Collaborative international research in clinical and longitudinal experience study in NMOSD
…, K McMullen, I Kister, Z Rimler… - Neurology …, 2019 - AAN Enterprises
Objective To develop a resource of systematically collected, longitudinal clinical data and
biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder …
biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder …
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
…, J Havla, Y Mao-Draayer, Z Rimler… - Journal of Neurology …, 2022 - jnnp.bmj.com
Background Patients with anti-aquaporin-4 antibody seropositive (AQP4-IgG+) neuromyelitis
optica spectrum disorders (NMOSDs) frequently suffer from optic neuritis (ON) leading to …
optica spectrum disorders (NMOSDs) frequently suffer from optic neuritis (ON) leading to …
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO)
…, R Yildirim, U Tanriverdi, A Jacob, S Huda, Z Rimler… - BMJ open, 2020 - bmjopen.bmj.com
Purpose Optical coherence tomography (OCT) captures retinal damage in neuromyelitis
optica spectrum disorders (NMOSD). Previous studies investigating OCT in NMOSD have …
optica spectrum disorders (NMOSD). Previous studies investigating OCT in NMOSD have …
Antibody and T-cell responses to SARS-CoV-2 vaccines in MS patients on Ocrelizumab and other disease-modifying therapies: Preliminary results of an ongoing …
…, MJ Mulligan, J Kim, E Tardio, Z Rimler… - Multiple Sclerosis …, 2021 - pesquisa.bvsalud.org
Objective: To compare humoral and T-cell responses to COVID-19 vaccines in 400 MS
patients who were on Ocrelizumab ('OCR') v. other disease-modifying therapies ('non-OCR') …
patients who were on Ocrelizumab ('OCR') v. other disease-modifying therapies ('non-OCR') …